Therapeutic effects of nebulized verapamil on chronic obstructive pulmonary disease: A randomized and double‐blind clinical trial

• DOI: 10.1111/crj.13142
• Publication Date: 2020-01-04T06:34:38Z
• Authors: Rama Bozorgmehr; Maryam Edalatifard; Enayat Safavi; Besharat Rahimi; Fariba Ghorbani; Hamidreza Abtahi; Shahideh Amini; Guitti Pourdowlat
• Keywords: Male; Nebulizers and Vaporizers; Vital Capacity; Middle Aged; Calcium Channel Blockers; 3. Good health; Hospitalization; Pulmonary Disease, Chronic Obstructive; 03 medical and health sciences; Dyspnea; Treatment Outcome; 0302 clinical medicine; Double-Blind Method; Verapamil; Forced Expiratory Volume; Administration, Inhalation; Humans; Female; Aged

In this study, we assessed the clinical effect of inhaled verapamil on hospitalized COPD patients in a randomized and double-blind study.COPD randomly received 10 mg or 4 cc nebulized distilled water (DW) as placebo.Twenty enrolled each group with no difference baseline characteristics. Mean age was 64.95 ± 8.9 66.9 10.74 years control group; respectively, (P > 0.05). The mean dyspnea score 6.4 1.2 6.2 1.8 group, respectively decreased to 4.9 1.3 5.7 after intervention. change significantly higher, (22.43% 10.6% vs 8.7% 12.1%), P = 0.00. Unlike FEV1 value increased reached 1.17 0.4 L from 1.03 0.4. There significant decrease airway resistance both groups However, neither total lung capacity residual volume nor forced vital changed significantly. Moreover, oxygen saturation 4.8% 2.5% improvement 1 0.00). Smoker subjects, ones PAP more than 35 mm Hg obese benefit verapamil.The beneficial impact diminishing along its bronchodilatory would make selective calcium blocker agent therapeutic option COPD.